Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.

The Farapulse PFA system provides a non-thermal approach for ablating heart tissue related to atrial fibrillation.

Boston Scientific gets PDMA approval in Japan for FARAPULSE PFA System: Marlborough, Massachusetts Monday, September 30, 2024, 13:00 Hrs [IST] Boston Scientific Corporation, a glo ...

MARLBOROUGH, Mass., Sept. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the ...

A medical milestone has been achieved in Deep East Texas as the first Left Atrial Appendage Occlusion (LAAO) procedure ...

Boston Scientific Corporation (NYSE: BSX ) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the FARAPULSETM Pulsed Field Ablation (PFA) System. The ...

27, 2024 /PRNewswire/ -- Boston Scientific Corporation ... PFA System for cardiac ablation and the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device. Boston Scientific plans to launch ...

MARLBOROUGH, Mass., Sept. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the ...

[Image courtesy of Boston Scientific] Boston Scientific (NYSE ... announced today that Japan’s Pharmaceuticals and Medical Device Agency has approved Farapulse, which is indicated for the ...

Boston Scientific manufactures medical devices and ... traction in Europe for its next-generation WATCHMAN FLX, as well as contributions from accretive acquisitions are important growth drivers.